Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes

References

• American Diabetes Association. Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–5.
   Google Scholar
• Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636–643.
   PubMed Web of Science ®Google Scholar
• CDC. Department of Health and Human Services [homepage on the Internet]. National diabetes statistics report, 2014. [ updated 2014; cited 2015 May 15]. Available from: http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed Dec 31, 2015.
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13(1):81–99.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Althage MC, Ford EL, Wang S, et al. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem. 2008;283:18365–18376.
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741–750.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Evogliptin: first global approval. Drugs. 2015;75:2045–2049.
   PubMed Web of Science ®Google Scholar
• PipelineReview.com. Dong-A ST’s DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea. 2015. cited 2015 Dec 31]. Available from: http://www.pipelinereview.com/index.php/2015100259148/Small-Molecules/Dong-A-STs-DPP4-inhibitor-SUGANON-got-approved-for-type-2-diabetes-in-Korea.html.
   Google Scholar
• Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Invest. 2013;4:108–130.
   PubMed Web of Science ®Google Scholar
• Kim M-K, Chae YN, Kim HD, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012;90:21–29.
   PubMed Web of Science ®Google Scholar
• Gu N, Park MK, Kim TE, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709–1721.
   PubMed Web of Science ®Google Scholar
• Kim TE, Lim KS, Park MK, et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther. 2012;34:1986–1998.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kwak WY, Min JP, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011;21:3809–3812.
   PubMed Web of Science ®Google Scholar
• NCT02214693. PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients. cited 2015 Dec 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02214693.
   Google Scholar
• Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J. 2012;36:98–107.
   PubMedGoogle Scholar
• Jung CH, Park CY, Ahn KJ, et al. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31:295–306.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009;18(10):1495–1503.
   PubMed Web of Science ®Google Scholar
• Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061–1072.
   PubMed Web of Science ®Google Scholar
• Simon D. Epidemiological features of type 2 diabetes. Rev Prat. 2010;60(4):469–473.
   PubMedGoogle Scholar
• Bloomfield DM, Krishna R, Hreniuk D, et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol. 2009;49:937–946.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744.
   PubMed Web of Science ®Google Scholar
• Subbarayan S, Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother. 2011;12:1613–1622.
   PubMed Web of Science ®Google Scholar
• Ring A, Port A, Graefe-Mody EU, et al. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol. 2011;72:39–50.
   PubMed Web of Science ®Google Scholar
• Tropeano AI. Mechanism of diabetic complications: “therapeutic” perspectives. Ann Endocrinol (Paris). 2003;64(6):474–476.
   PubMedGoogle Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013;19:536–557.
   PubMed Web of Science ®Google Scholar
• Leibowitz G, Cahn A, Bhatt DL, et al. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015;17:487–494.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Tunceli K, Qiu Y, et al. Progression to insulin therapy among type 2 diabetes patients treated with sitagliptin or sulfonylurea plus metformin dual therapy. Diabetes Obes Metab. 2015;17:956–964.
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441–1467.
   PubMed Web of Science ®Google Scholar
• He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51:147–162.
   PubMed Web of Science ®Google Scholar
• Li H, Yang L, Tou CK, et al. Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Clin Drug Investig. 2012;32:465–473.
   PubMed Web of Science ®Google Scholar
• Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2003;16:5–22.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.
   PubMed Web of Science ®Google Scholar
• Weir GC, Bonner-Weir S. Islet beta cell mass in diabetes and how it relates to function, birth, and death. Ann NY Acad Sci. 2013;1281:92–105.
   PubMed Web of Science ®Google Scholar
• Song I, Muller C, Louw J, et al. Regulating the beta cell mass as a strategy for type-2 diabetes treatment. Curr Drug Targets. 2015;16(5):516–524.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46(2):145–154.
   PubMed Web of Science ®Google Scholar
• Mondragon A, Davidsson D, Kyriakoudi S, et al. Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia. PLoS One. 2014;9(8):e104873.
   Google Scholar
• Omar BA, Vikman J, Winzell MS, et al. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia. 2013;56(8):1752–1760.
   PubMed Web of Science ®Google Scholar
• Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Res Clin Pract. 2011;91:72–79.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329–1339.
   PubMed Web of Science ®Google Scholar
• Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171–180.
   PubMed Web of Science ®Google Scholar
• Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–698.
   PubMed Web of Science ®Google Scholar
• Chae YN, Kim TH, Kim MK, et al. Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased ppargc1a in white adipose tissue in obese mice. PLoS One. 2015 Dec 3;10(12):e0144064.
   PubMed Web of Science ®Google Scholar
• Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes. 2010;60:218–226.
   PubMed Web of Science ®Google Scholar
• Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the UK primary care setting. Diabetes Care. 2005;28(1):20–26.
   PubMed Web of Science ®Google Scholar
• Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes a retrospective cohort study. Diabetes Care;. 2003;26(11):2983–2989.
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54(1):146–151.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485–494.
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, Von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11(3):1–10.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57–64.
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495–509.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.
   PubMed Web of Science ®Google Scholar